BioCentury
ARTICLE | Financial News

CardioDx revives IPO plans

April 30, 2014 12:43 AM UTC

CardioDx Inc. (Palo Alto, Calif.) revived plans for an IPO on NASDAQ. The company had planned to sell 5 million shares at $14-$16 and would have raised $75 million at the $15 midpoint. In November, CardioDx postponed its IPO due to market conditions, according to a Wall Streeter who asked to remain anonymous. On Tuesday, the company filed an S-1A that no longer contains a share price or proposed number of shares. Jefferies; Piper Jaffray; and William Blair are listed as underwriters.

CardioDx markets its Corus CAD test in the U.S., which aids in ruling out obstructive coronary artery disease (CAD) in non-diabetic patients who have symptoms suggestive of CAD. The blood-based test, which measures the expression levels of 23 genes and other patient characteristics, is covered under Medicare Part B. ...